Drug Profile


Alternative Names: Elinogrel potassium; PRT 128; PRT060128; PRT060128 potassium

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Portola Pharmaceuticals
  • Class Antiplatelets; Hydrazines; Quinazolines; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Myocardial infarction

Most Recent Events

  • 16 Jan 2012 Novartis terminates its licence for elinogrel
  • 12 Jan 2012 Discontinued - Phase-II for Acute coronary syndromes in Canada (PO)
  • 12 Jan 2012 Discontinued - Phase-II for Myocardial infarction in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top